{"gene":"FAM3A","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2014,"finding":"FAM3A is localized in mitochondria, where it increases ATP production and secretion in hepatocytes. Released ATP activates P2 receptors, triggering PLC/IP3R-mediated Ca2+ elevation, which activates calmodulin (CaM), which in turn activates PI3K p110α/Akt signaling in an insulin-independent manner to suppress hepatic gluconeogenesis and lipogenesis.","method":"Subcellular fractionation, siRNA knockdown, adenoviral overexpression, pharmacological inhibition of P2 receptors/PLC/IP3R/CaM, in vivo mouse models (db/db, HFD)","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal pharmacological inhibitors, genetic KD/OE, in vivo and in vitro confirmation, replicated across multiple subsequent studies","pmids":["24806753"],"is_preprint":false},{"year":2013,"finding":"PPARγ directly binds a peroxisome proliferator response element (PPRE) at -1258/-1246 in the human FAM3A promoter to transcriptionally activate FAM3A expression; site-directed mutagenesis of this PPRE abolished the stimulatory effect.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), site-directed mutagenesis, PPARγ agonist/antagonist treatment, PPARγ overexpression","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP plus mutagenesis plus reporter assay in single lab with multiple orthogonal methods","pmids":["23562554"],"is_preprint":false},{"year":2014,"finding":"FAM3A localizes to mitochondria in VSMCs and promotes ATP production and release. Released ATP activates the P2Y1 receptor to stimulate Akt (PI3K-dependent) and ERK1/2 (PI3K-independent) pathways, driving VSMC proliferation and migration. FAM3A overexpression exacerbates neointima formation after balloon injury in rat carotid artery.","method":"Subcellular fractionation, adenoviral overexpression, siRNA knockdown, P2 receptor antagonist suramin, P2Y1 siRNA knockdown, PI3K inhibitor, in vivo rat balloon injury model","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain/loss-of-function, pathway dissection with selective inhibitors, in vivo model; replicated in subsequent studies","pmids":["24857820"],"is_preprint":false},{"year":2017,"finding":"NFE2 transcriptionally induces miR-423-5p, which directly targets FAM3A mRNA to repress its expression, thereby suppressing the FAM3A-ATP-Akt pathway, promoting hepatic gluconeogenesis and lipogenesis under obese conditions.","method":"miRNA target site prediction + luciferase reporter, hepatic adenoviral miR-423-5p overexpression/inhibition, NFE2 overexpression, in vivo mouse models (db/db, HFD)","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Moderate — luciferase validation of direct miRNA targeting, gain/loss-of-function in vivo and in vitro, pathway epistasis confirmed","pmids":["28411267"],"is_preprint":false},{"year":2019,"finding":"Stat3 transcriptionally activates Fam3a in muscle stem cells; Fam3a is a secreted cytokine-like protein that promotes oxidative phosphorylation/mitochondrial respiration to drive myogenic commitment and skeletal muscle development. Recombinant Fam3a rescues mitochondrial respiration and myogenic commitment defects in Stat3-ablated muscle stem cells.","method":"Stat3 genetic ablation, recombinant Fam3a treatment in vitro and in vivo, Fam3a knockdown/KO in mice, Seahorse respirometry, myogenic differentiation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Stat3 upstream of Fam3a), rescue experiment with recombinant protein in vitro and in vivo, multiple orthogonal readouts","pmids":["30996264"],"is_preprint":false},{"year":2017,"finding":"FAM3A localized to mitochondria promotes ATP production in 3T3-L1 preadipocytes; released ATP activates P2 receptors to stimulate Akt phosphorylation, which enhances adipogenesis. P2 receptor inhibition blocks FAM3A-induced adipogenesis.","method":"Subcellular fractionation, adenoviral overexpression, siRNA knockdown, P2 receptor antagonist, ATP measurement, lipid staining","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function plus pharmacological inhibition, single lab","pmids":["28515350"],"is_preprint":false},{"year":2017,"finding":"FAM3A protects against liver ischemia-reperfusion injury by activating Akt survival pathway (ATP-P2 receptor-dependent), repressing apoptosis, inflammation, and oxidative stress; PPARγ agonist rosiglitazone's hepatoprotective effects are dependent on FAM3A.","method":"FAM3A-deficient (KO) mice, rosiglitazone treatment, hepatocyte overexpression/deficiency, P2 receptor inhibition, in vivo IRI model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO + pharmacological dependence demonstrated, single lab","pmids":["28562339"],"is_preprint":false},{"year":2019,"finding":"Endothelial FAM3A (mitochondrial) increases ATP production and secretion; extracellular ATP activates P2 receptors to elevate cytosolic Ca2+, which enhances CREB phosphorylation and CREB recruitment to the VEGFA promoter, thereby activating VEGFA transcription and promoting angiogenesis.","method":"Adenoviral and AAV-mediated overexpression/knockdown, tube formation/migration/proliferation assays, hind limb ischemia mouse model, intracellular Ca2+ imaging, ChIP/promoter analysis","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function in vitro and in vivo, mechanistic pathway traced to VEGFA promoter, single lab","pmids":["31000420"],"is_preprint":false},{"year":2020,"finding":"In VSMCs, Angiotensin II activates HSF1 (heat shock factor 1), which transcriptionally upregulates FAM3A expression; elevated FAM3A enhances ATP production and activates the ATP-P2 receptor pathway, promoting VSMC phenotypic switch from contractile to proliferative. VSMC-specific FAM3A deletion reduces vessel contractility, blood pressure, and attenuates Ang II-induced hypertension and cardiac hypertrophy in mice.","method":"VSMC-specific Fam3a conditional KO mice, Ang II infusion model, HSF1 ChIP/overexpression, HSF1 inhibitor treatment, spontaneously hypertensive rats","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO with clear phenotype, upstream regulator (HSF1) identified by ChIP, pharmacological validation with HSF1 inhibitor, replicated in multiple hypertensive models","pmids":["32279581"],"is_preprint":false},{"year":2020,"finding":"FAM3A plays crucial roles in pancreatic β cells: it promotes ATP synthesis, elevates cytosolic Ca2+ to stimulate insulin secretion, and releases ATP extracellularly to activate CaM as a co-activator of FOXA2, stimulating PDX1 gene transcription. β cell-specific FAM3A KO mice display markedly blunted insulin secretion and glucose intolerance.","method":"β cell-specific FAM3A KO mice, islet-specific adenoviral overexpression, CaM inhibitor, FOXA2 ChIP on PDX1 promoter, Ca2+ measurement, glucose tolerance test","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO, mechanistic pathway traced to PDX1 transcription via CaM-FOXA2, multiple orthogonal methods","pmids":["31944392"],"is_preprint":false},{"year":2020,"finding":"Doxepin stimulates the nuclear translocation of HNF4α, which then promotes FAM3A transcription in hepatocytes; FAM3A deficiency abolishes doxepin's effects on ATP production, Akt activation, gluconeogenesis suppression, and lipid reduction.","method":"Drug-repurposing screen, HNF4α nuclear translocation assay, FAM3A KO mice on HFD, in vivo metabolic phenotyping","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FAM3A KO epistasis establishes pathway dependence, HNF4α nuclear translocation shown, single lab","pmids":["32312868"],"is_preprint":false},{"year":2022,"finding":"FAM3A localizes to the mitochondrial matrix where it physically interacts with F1-ATP synthase (F1-ATPS) to directly activate ATP synthesis; released ATP subsequently activates P2 receptor-Akt-CREB signaling to induce FOXD3 expression. FOXD3 synchronously stimulates transcription of ATP synthase subunit genes and assembly factors to increase ATP synthase assembly and capacity, constituting a positive regulatory loop.","method":"Subcellular fractionation, co-immunoprecipitation (FAM3A with F1-ATPS), FOXD3 KO/KD, CREB pathway inhibition, RNA sequencing, in vivo FAM3A-deficient mice with metabolic phenotyping","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct physical interaction by co-IP, functional consequence demonstrated, epistatic loop confirmed by FOXD3 KO, single lab with multiple orthogonal methods","pmids":["36470472"],"is_preprint":false},{"year":2022,"finding":"FAM3A-induced ATP release activates P2 receptors, promoting CaM translocation from cytoplasm to nucleus, where CaM acts as a co-activator of FOXA2 to transcribe CPT2 (carnitine palmitoyltransferase 2), increasing fatty acid oxidation and reducing lipid deposition. Imipramine activates this FAM3A-ATP-CaM-FOXA2-CPT2 pathway; FAM3A deficiency abolishes imipramine's lipid-lowering effect.","method":"RNA sequencing, CaM nuclear translocation assay, FOXA2 ChIP on CPT2 promoter, FAM3A KO mice on HFD, imipramine administration","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 2 / Moderate — transcriptomic identification of downstream target, ChIP, CaM nuclear localization assay, KO epistasis, single lab with multiple orthogonal methods","pmids":["35995281"],"is_preprint":false},{"year":2023,"finding":"FAM3A induces KLF4 ubiquitination and reduces its phosphorylation and nuclear localization in VSMCs, maintaining well-differentiated VSMC status and inhibiting VSMC transformation toward macrophage-, chondrocyte-, osteogenic-, mesenchymal-, and fibroblast-like phenotypes, thereby attenuating abdominal aortic aneurysm (AAA) formation.","method":"FAM3A overexpression/supplementation in murine AAA models, ubiquitination assays, KLF4 phosphorylation and nuclear localization assays, single-cell analyses, AAA histology","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KLF4 ubiquitination and nuclear localization demonstrated, in vivo rescue, single lab","pmids":["37660071"],"is_preprint":false},{"year":2024,"finding":"FAM3A stimulates expression of the ATP-permeable channel PANX1 via HSF1 in hepatocytes; PANX1 mediates ATP release required for FAM3A's suppression of hepatic gluconeogenesis and lipogenesis. FAM3A overexpression fails to inhibit gluconeogenic/lipogenic genes in PANX1-deficient hepatocytes, establishing PANX1 as the conduit for FAM3A-driven ATP release.","method":"Co-immunoprecipitation with mass spectrometry, PANX1 global KO mice, hepatic PANX1 overexpression/knockdown via adenovirus/AAV, metabolic tolerance tests, OGTT/ITT/PTT, FAM3A overexpression in PANX1-KO hepatocytes","journal":"Military Medical Research","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP/MS for protein-protein interaction, genetic KO epistasis, in vivo and in vitro validation, multiple metabolic readouts","pmids":["38937853"],"is_preprint":false},{"year":2024,"finding":"In pancreatic α-cells, FAM3A deficiency increases Nr4a2 expression; Nr4a2 forms a complex with FOXA2 to facilitate FOXA2 nuclear localization, and FOXA2 negatively regulates PCSK1 (PC1/3) transcription at specific promoter binding sites. Loss of α-cell FAM3A therefore de-represses PC1/3, shifting proglucagon processing from glucagon toward GLP-1 production, improving glucose tolerance via paracrine insulin secretion.","method":"α cell-specific Fam3a KO mice, transcriptomic analysis, Nr4a2 siRNA/overexpression, FOXA2 nuclear translocation assay, dual-luciferase reporter (Pcsk1 promoter), Nr4a2-FOXA2 co-IP, scRNA-seq correlation analysis, Ex9 GLP-1R antagonist in vivo","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO, luciferase reporter with promoter mutagenesis, co-IP for Nr4a2-FOXA2 complex, in vivo rescue with receptor antagonist, multiple orthogonal methods","pmids":["39362520"],"is_preprint":false},{"year":2024,"finding":"FAM3A promotes PI3K/AKT/NRF2 signaling to block mitochondrial ROS accumulation; excess mt-ROS activates the NLRP3 inflammasome and Caspase-1, which cleaves GSDMD, pro-IL-1β, and pro-IL-18 to mediate pyroptosis in renal tubular cells. FAM3A KO worsens AKI and tubular pyroptosis, while FAM3A overexpression or NRF2 activator alleviates it; NRF2 deletion blocks FAM3A's anti-pyroptotic function.","method":"FAM3A KO and overexpression in renal ischemia/reperfusion model, NRF2 activator/inhibitor, Caspase-1/GSDMD cleavage assays, NLRP3 inflammasome activation assays, mt-ROS measurement","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO/OE with epistasis through NRF2, mechanistic pathway traced to pyroptosis effectors, single lab","pmids":["38875957"],"is_preprint":false},{"year":2015,"finding":"FAM3A is subcellularly located in mitochondria of neuronal HT22 cells. FAM3A overexpression protects against H2O2-induced injury by reducing ROS and preserving ATP production; PI3K/Akt (but not MEK/ERK) pathway inhibition partially abolishes FAM3A-induced neuroprotection.","method":"Fluorescence subcellular localization, lentiviral overexpression, selective kinase inhibitors (PI3K/Akt vs MEK/ERK), cell viability, flow cytometry apoptosis, cytochrome c release, caspase-3 activation","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — localization confirmed, pathway inhibitor dissection, single lab, no rescue with reconstituted protein","pmids":["26492522"],"is_preprint":false},{"year":2016,"finding":"FAM3A overexpression attenuates ER stress-induced mitochondrial dysfunction in neuronal HT22 cells by inverting tunicamycin-induced decrease of Wnt signaling through the CHOP pathway; CHOP siRNA knockdown confirmed FAM3A's protection is mediated via CHOP-Wnt axis.","method":"Lentiviral overexpression, tunicamycin ER stress model, CHOP siRNA, mitochondrial membrane potential, cytochrome c release, mitochondrial swelling/Ca2+ buffering in isolated mitochondria","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isolated mitochondria experiments plus CHOP siRNA epistasis, single lab","pmids":["26939760"],"is_preprint":false},{"year":2017,"finding":"FAM3A overexpression in glutamate-injured PC12 neurons decreases surface expression of mGluR1/5, disrupts the STIM1-Orai1 interaction (confirmed by co-immunoprecipitation), and attenuates store-operated Ca2+ entry (SOCE) and IP3R-mediated ER Ca2+ release, thereby preserving intracellular Ca2+ homeostasis and reducing neuronal apoptosis.","method":"Co-immunoprecipitation (STIM1/Orai1), Ca2+ imaging, lentiviral overexpression, western blot for receptor surface expression, thapsigargin-induced SOCE assay","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP for STIM1-Orai1 disruption by FAM3A, Ca2+ imaging, single lab","pmids":["29241198"],"is_preprint":false},{"year":2016,"finding":"C/EBPβ directly binds to the FAM3A promoter and acts as a transcriptional activator; mutation of C/EBPβ binding sites dramatically reduces FAM3A promoter activity. FAM3A overexpression inhibits preadipocyte-to-adipocyte differentiation.","method":"Dual luciferase reporter, electrophoretic mobility shift assay (EMSA), C/EBPβ binding site mutagenesis, FAM3A overexpression with Oil Red O staining","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — EMSA and reporter mutagenesis for transcriptional regulation, functional differentiation assay, single lab","pmids":["27688071"],"is_preprint":false},{"year":2021,"finding":"Both intracellular and extracellular ATP contribute to FAM3A-induced PDX1 expression, insulin secretion, and β-cell proliferation. FAM3A-induced Ca2+ elevation, PDX1 expression, and insulin secretion are repressed by P2 receptor inhibitors, L-type Ca2+ channel inhibitors, or CaM inhibitor in pancreatic β cells.","method":"siRNA transfection in mouse islets, in vivo glucose tolerance test, P2 receptor inhibitor, L-type Ca2+ channel inhibitor, CaM inhibitor, intracellular/extracellular ATP measurement","journal":"Experimental and clinical endocrinology & diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors dissect pathway, in vivo siRNA epistatsis, single lab, consistent with prior study (PMID 31944392)","pmids":["34592773"],"is_preprint":false},{"year":2023,"finding":"FAM3A deficiency in cardiomyocytes reduces basal, ATP-linked respiration and respiratory reserve, and is associated with enlarged mitochondria, elevated mitochondrial Ca2+, higher mPTP opening, lower mitochondrial membrane potential, and elevated apoptosis. The mitochondrial dynamics protein Opa1 contributes to FAM3A's effects in cardiomyocytes.","method":"Fam3a-/- mice with MI model, Seahorse respirometry in isolated cardiomyocytes, transmission electron microscopy, mPTP opening assay, mitochondrial Ca2+ and membrane potential measurements, Opa1 analysis","journal":"Journal of cardiovascular translational research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO phenotype with multiple mitochondrial function readouts, Opa1 identified as contributing factor, single lab","pmids":["37014466"],"is_preprint":false},{"year":2025,"finding":"KLF4 directly binds to the FAM3A promoter (confirmed by CHIP and luciferase assays) and transcriptionally upregulates FAM3A expression in Ang II-stimulated VSMCs, with FAM3A mediating Ang II-induced proliferation and migration through PI3K/AKT pathway activation.","method":"Bioinformatics, luciferase reporter, chromatin immunoprecipitation (CHIP), KLF4 KD/OE, FAM3A siRNA, PI3K/AKT western blot, EdU proliferation, transwell/scratch migration","journal":"Peptides","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and luciferase, functional epistasis, single lab","pmids":["40015605"],"is_preprint":false},{"year":2012,"finding":"Hoxa13 binds to the FAM3A promoter and enhances its transcriptional activity in neuronal cells; the Snhg8/miR-384/Hoxa13/FAM3A axis regulates chronic cerebral ischemia-induced neuronal apoptosis.","method":"Promoter activity assay (Hoxa13 binding to FAM3A promoter), miRNA target site validation, Snhg8 and miR-384 overexpression/knockdown, in vivo ischemia mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding assay for Hoxa13, functional apoptosis epistasis shown, single lab","pmids":["31165722"],"is_preprint":false}],"current_model":"FAM3A is a mitochondrial matrix protein that physically interacts with F1-ATP synthase to directly stimulate ATP synthesis; the resulting intracellular ATP is released extracellularly via the PANX1 channel (regulated by HSF1) and via other mechanisms, and extracellular ATP activates P2 purinergic receptors to trigger downstream signaling cascades—including Ca2+/calmodulin-dependent PI3K-p110α/Akt activation, CREB-FOXD3-mediated ATP synthase assembly reinforcement, CaM-FOXA2-driven CPT2 and PDX1 transcription, and VEGFA-mediated angiogenesis—that collectively suppress hepatic gluconeogenesis and lipogenesis, promote β-cell insulin secretion and PDX1 expression, drive muscle stem cell myogenic commitment via oxidative phosphorylation, regulate VSMC phenotype and blood pressure, and protect multiple cell types from oxidative, ischemic, and ER stress-induced injury; FAM3A expression is transcriptionally regulated by PPARγ, HNF4α, C/EBPβ, STAT3, HSF1, KLF4, and Hoxa13, and is repressed post-transcriptionally by miR-423-5p (driven by NFE2) and miR-1299."},"narrative":{"mechanistic_narrative":"FAM3A is a mitochondrial matrix protein that drives ATP-dependent signaling to govern cellular metabolism, survival, and proliferation across hepatic, pancreatic, vascular, muscle, and neuronal tissues [PMID:24806753, PMID:36470472]. Within the mitochondrial matrix it physically interacts with F1-ATP synthase to directly stimulate ATP synthesis, and the resulting ATP is released extracellularly—in hepatocytes through the HSF1-regulated, ATP-permeable channel PANX1—to act in an autocrine/paracrine manner [PMID:36470472, PMID:38937853]. Released ATP engages P2 purinergic receptors (including P2Y1), triggering PLC/IP3R-mediated Ca2+ elevation and calmodulin activation that drives PI3K-p110α/Akt signaling independently of insulin [PMID:24806753, PMID:24857820]. Downstream of this ATP-P2-Akt axis, FAM3A feeds multiple transcriptional programs: a CREB-FOXD3 loop that reinforces ATP synthase assembly [PMID:36470472], a calmodulin-FOXA2 axis driving CPT2-dependent fatty acid oxidation and PDX1 transcription [PMID:35995281, PMID:31944392], and CREB-driven VEGFA expression for angiogenesis [PMID:31000420]. Functionally, FAM3A suppresses hepatic gluconeogenesis and lipogenesis [PMID:24806753, PMID:38937853], promotes β-cell insulin secretion and survival [PMID:31944392], regulates pancreatic α-cell proglucagon processing via an Nr4a2-FOXA2-PCSK1 axis [PMID:39362520], drives muscle stem cell myogenic commitment through oxidative phosphorylation [PMID:30996264], controls VSMC phenotype and blood pressure [PMID:32279581, PMID:37660071], and protects diverse cell types from oxidative, ischemic, and ER stress by preserving ATP, limiting ROS, and engaging Akt/NRF2 survival signaling [PMID:28562339, PMID:38875957, PMID:26492522]. FAM3A transcription is activated by PPARγ, HNF4α, C/EBPβ, STAT3, HSF1, KLF4, and Hoxa13, and is repressed post-transcriptionally by miR-423-5p [PMID:23562554, PMID:27688071, PMID:30996264, PMID:32279581, PMID:40015605, PMID:28411267].","teleology":[{"year":2012,"claim":"Established a transcriptional activator and a regulatory non-coding RNA circuit controlling FAM3A in neurons, linking it to ischemic neuronal apoptosis before its biochemical role was clear.","evidence":"Hoxa13 promoter-binding assay and Snhg8/miR-384 gain/loss-of-function in an in vivo cerebral ischemia mouse model","pmids":["31165722"],"confidence":"Medium","gaps":["Did not define FAM3A's molecular activity downstream of transcription","Promoter binding not extended to direct biochemical FAM3A function"]},{"year":2013,"claim":"Identified the first direct transcriptional activator of FAM3A, placing it downstream of nuclear receptor signaling.","evidence":"Luciferase reporter, ChIP, and PPRE site-directed mutagenesis with PPARγ agonist/antagonist in human cells","pmids":["23562554"],"confidence":"High","gaps":["Did not establish FAM3A's downstream effector mechanism","Physiological context of PPARγ-FAM3A axis not tested in vivo here"]},{"year":2014,"claim":"Defined FAM3A's core mechanism—mitochondrial ATP production and release activating an extracellular P2 receptor-Ca2+-CaM-PI3K/Akt cascade to suppress hepatic gluconeogenesis and lipogenesis insulin-independently.","evidence":"Subcellular fractionation, KD/OE, orthogonal pharmacological inhibition of P2/PLC/IP3R/CaM, and db/db and HFD mouse models","pmids":["24806753"],"confidence":"High","gaps":["Did not identify how FAM3A mechanistically stimulates ATP synthesis","ATP release conduit not yet identified"]},{"year":2014,"claim":"Showed the same mitochondrial ATP-P2 receptor mechanism operates in vascular smooth muscle, where it drives proliferation/migration via P2Y1-Akt and ERK1/2, generalizing FAM3A beyond liver.","evidence":"Fractionation, reciprocal OE/KD, suramin/P2Y1 siRNA/PI3K inhibitors, and rat carotid balloon injury model","pmids":["24857820"],"confidence":"High","gaps":["Branch point between Akt and ERK1/2 downstream of P2Y1 not resolved","No direct ATP synthase interaction shown"]},{"year":2015,"claim":"Extended FAM3A's cytoprotective function to neurons, linking ATP preservation and ROS reduction to PI3K/Akt-dependent survival under oxidative stress.","evidence":"Subcellular localization, lentiviral OE, selective PI3K/Akt vs MEK/ERK inhibitors, apoptosis and cytochrome c assays in HT22 cells","pmids":["26492522"],"confidence":"Medium","gaps":["No rescue with reconstituted protein","Mechanism of ROS reduction not defined"]},{"year":2016,"claim":"Added C/EBPβ as a direct FAM3A activator and uncovered ER-stress protection via a CHOP-Wnt axis, broadening transcriptional control and stress-protective scope.","evidence":"Luciferase/EMSA/mutagenesis (C/EBPβ); tunicamycin model with CHOP siRNA and isolated-mitochondria assays in HT22 cells","pmids":["27688071","26939760"],"confidence":"Medium","gaps":["How FAM3A modulates Wnt/CHOP signaling biochemically is unresolved","C/EBPβ regulation not tested in vivo"]},{"year":2017,"claim":"Identified miR-423-5p (driven by NFE2) as a direct post-transcriptional repressor of FAM3A, providing a mechanism for FAM3A downregulation in obesity, and extended the ATP-Akt axis to adipogenesis and liver ischemia protection.","evidence":"Luciferase miRNA targeting + in vivo miR-423-5p/NFE2 manipulation; P2-inhibitor adipogenesis assays; FAM3A KO + rosiglitazone IRI model","pmids":["28411267","28515350","28562339"],"confidence":"High","gaps":["Tissue-specificity of miR-423-5p regulation incompletely mapped","Opposite metabolic outcomes (adipogenesis vs gluconeogenesis suppression) not reconciled mechanistically"]},{"year":2017,"claim":"Defined a neuronal Ca2+-homeostasis mechanism in which FAM3A disrupts STIM1-Orai1 and dampens store-operated Ca2+ entry to reduce apoptosis.","evidence":"STIM1/Orai1 co-IP, Ca2+ imaging, SOCE assays, and surface receptor blots in glutamate-injured PC12 cells","pmids":["29241198"],"confidence":"Medium","gaps":["Single co-IP without reciprocal/structural validation","Relationship between this Ca2+ effect and the mitochondrial ATP role unclear"]},{"year":2019,"claim":"Established FAM3A as a STAT3-induced secreted factor promoting oxidative phosphorylation and myogenic commitment, and traced an endothelial CREB-VEGFA angiogenic program.","evidence":"Stat3 ablation + recombinant Fam3a rescue, Seahorse, Fam3a KO mice; endothelial OE/KD with hind-limb ischemia model and VEGFA promoter ChIP","pmids":["30996264","31000420"],"confidence":"High","gaps":["Reconciliation of mitochondrial vs secreted-cytokine modes of action not addressed","Receptor mediating any secreted FAM3A action unidentified"]},{"year":2020,"claim":"Mapped tissue-specific transcriptional inputs and effector programs: HSF1-driven FAM3A in VSMC hypertension, HNF4α-driven hepatic FAM3A, and a β-cell CaM-FOXA2-PDX1 axis controlling insulin secretion.","evidence":"VSMC- and β-cell-specific Fam3a KO mice, HSF1 ChIP/inhibitor, doxepin/HNF4α translocation, FOXA2 ChIP on PDX1 promoter, Ang II and GTT models","pmids":["32279581","31944392","32312868"],"confidence":"High","gaps":["How a single mitochondrial protein produces tissue-divergent transcriptional outputs not unified","Direct ATP synthase engagement still inferred, not shown"]},{"year":2022,"claim":"Resolved FAM3A's biochemical mechanism by demonstrating direct physical interaction with F1-ATP synthase to stimulate ATP synthesis, and uncovered a CREB-FOXD3 feed-forward loop reinforcing ATP synthase assembly, plus a CaM-FOXA2-CPT2 fatty-acid-oxidation arm.","evidence":"Co-IP (FAM3A-F1-ATPS), FOXD3 KO/KD, CREB inhibition, RNA-seq; FOXA2 ChIP on CPT2 promoter with FAM3A KO + imipramine HFD models","pmids":["36470472","35995281"],"confidence":"High","gaps":["Structural basis of FAM3A-F1-ATPS interaction unknown","Stoichiometry and direct catalytic effect on ATP synthase not quantified"]},{"year":2023,"claim":"Defined non-ATP regulatory outputs in vasculature—FAM3A induces KLF4 ubiquitination to maintain VSMC differentiation and attenuate aneurysm—and a KLF4 feedback loop activating FAM3A, alongside cardiomyocyte mitochondrial dynamics via Opa1.","evidence":"AAA models with KLF4 ubiquitination/nuclear-localization assays; KLF4 ChIP/luciferase; Fam3a-/- MI model with Seahorse, TEM, mPTP and Opa1 analysis","pmids":["37660071","40015605","37014466"],"confidence":"Medium","gaps":["Whether KLF4 ubiquitination is ATP-dependent or a distinct activity unclear","Mechanism linking FAM3A to Opa1 not defined"]},{"year":2024,"claim":"Identified PANX1 as the HSF1-induced conduit for FAM3A-driven ATP release in hepatocytes, defined a NRF2-dependent anti-pyroptotic mechanism, and uncovered an α-cell Nr4a2-FOXA2-PCSK1 axis shifting proglucagon processing toward GLP-1.","evidence":"Co-IP/MS, PANX1 KO and hepatic OE/KD with metabolic tests; FAM3A KO/OE renal I/R with NRF2 epistasis and GSDMD/Caspase-1 assays; α-cell-specific Fam3a KO with Pcsk1 luciferase and Nr4a2-FOXA2 co-IP","pmids":["38937853","38875957","39362520"],"confidence":"High","gaps":["Whether PANX1 is the universal ATP conduit across all FAM3A-expressing tissues untested","How FAM3A loss elevates Nr4a2 mechanistically unresolved"]},{"year":null,"claim":"The structural basis and stoichiometry of FAM3A's interaction with F1-ATP synthase, and how a single mitochondrial protein generates tissue-divergent transcriptional and non-ATP (KLF4 ubiquitination, STIM1-Orai1) outputs, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of FAM3A or its ATP synthase complex","Mechanism by which a matrix protein controls cytoplasmic/nuclear events beyond ATP release is unclear","Whether secreted and mitochondrial FAM3A pools are functionally distinct is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[11,0]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,2,5,11,17]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,12,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,7]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[16,17,18]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[11,9,12,15]}],"complexes":[],"partners":["ATP5F1 (F1-ATP SYNTHASE)","PANX1","FOXD3","FOXA2","NR4A2","KLF4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P98173","full_name":"Protein FAM3A","aliases":["Cytokine-like protein 2-19"],"length_aa":230,"mass_kda":25.2,"function":"May act as a defensin against invading fungal microorganisms","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P98173/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FAM3A","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FAM3A","total_profiled":1310},"omim":[{"mim_id":"608619","title":"FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER D; FAM3D","url":"https://www.omim.org/entry/608619"},{"mim_id":"608618","title":"FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER C; FAM3C","url":"https://www.omim.org/entry/608618"},{"mim_id":"608617","title":"FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER B; FAM3B","url":"https://www.omim.org/entry/608617"},{"mim_id":"300492","title":"FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER A; FAM3A","url":"https://www.omim.org/entry/300492"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli rim","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Mitotic chromosome","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FAM3A"},"hgnc":{"alias_symbol":["DXS560S","2-19","XAP-7"],"prev_symbol":[]},"alphafold":{"accession":"P98173","domains":[{"cath_id":"-","chopping":"57-223","consensus_level":"high","plddt":97.6647,"start":57,"end":223}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P98173","model_url":"https://alphafold.ebi.ac.uk/files/AF-P98173-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P98173-F1-predicted_aligned_error_v6.png","plddt_mean":88.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FAM3A","jax_strain_url":"https://www.jax.org/strain/search?query=FAM3A"},"sequence":{"accession":"P98173","fasta_url":"https://rest.uniprot.org/uniprotkb/P98173.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P98173/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P98173"}},"corpus_meta":[{"pmid":"24806753","id":"PMC_24806753","title":"FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24806753","citation_count":101,"is_preprint":false},{"pmid":"28411267","id":"PMC_28411267","title":"NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.","date":"2017","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/28411267","citation_count":79,"is_preprint":false},{"pmid":"30996264","id":"PMC_30996264","title":"The Stat3-Fam3a axis promotes muscle stem cell myogenic lineage progression by inducing mitochondrial respiration.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30996264","citation_count":55,"is_preprint":false},{"pmid":"32279581","id":"PMC_32279581","title":"VSMC-Specific Deletion of FAM3A Attenuated Ang II-Promoted Hypertension and Cardiovascular Hypertrophy.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/32279581","citation_count":43,"is_preprint":false},{"pmid":"38875957","id":"PMC_38875957","title":"FAM3A plays a key role in protecting against tubular cell pyroptosis and acute kidney injury.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38875957","citation_count":40,"is_preprint":false},{"pmid":"23562554","id":"PMC_23562554","title":"FAM3A is a target gene of peroxisome proliferator-activated receptor gamma.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23562554","citation_count":35,"is_preprint":false},{"pmid":"26492522","id":"PMC_26492522","title":"FAM3A Protects HT22 Cells Against Hydrogen Peroxide-Induced Oxidative Stress Through Activation of PI3K/Akt but not MEK/ERK Pathway.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26492522","citation_count":33,"is_preprint":false},{"pmid":"24857820","id":"PMC_24857820","title":"FAM3A promotes vascular smooth muscle cell proliferation and migration and exacerbates neointima formation in rat artery after balloon injury.","date":"2014","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/24857820","citation_count":31,"is_preprint":false},{"pmid":"28562339","id":"PMC_28562339","title":"FAM3A mediates PPARγ's protection in liver ischemia-reperfusion injury by activating Akt survival pathway and repressing inflammation and oxidative stress.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28562339","citation_count":30,"is_preprint":false},{"pmid":"37660071","id":"PMC_37660071","title":"FAM3A reshapes VSMC fate specification in abdominal aortic aneurysm by regulating KLF4 ubiquitination.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37660071","citation_count":27,"is_preprint":false},{"pmid":"26939760","id":"PMC_26939760","title":"FAM3A attenuates ER stress-induced mitochondrial dysfunction and apoptosis via CHOP-Wnt pathway.","date":"2016","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/26939760","citation_count":26,"is_preprint":false},{"pmid":"31165722","id":"PMC_31165722","title":"Mechanism of Snhg8/miR-384/Hoxa13/FAM3A axis regulating neuronal apoptosis in ischemic mice model.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31165722","citation_count":24,"is_preprint":false},{"pmid":"32312868","id":"PMC_32312868","title":"Repurposing Doxepin to Ameliorate Steatosis and Hyperglycemia by Activating FAM3A Signaling Pathway.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/32312868","citation_count":23,"is_preprint":false},{"pmid":"31000420","id":"PMC_31000420","title":"Endothelial FAM3A positively regulates post-ischaemic angiogenesis.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31000420","citation_count":20,"is_preprint":false},{"pmid":"28515350","id":"PMC_28515350","title":"FAM3A enhances adipogenesis of 3T3-L1 preadipocytes via activation of ATP-P2 receptor-Akt signaling pathway.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28515350","citation_count":19,"is_preprint":false},{"pmid":"31944392","id":"PMC_31944392","title":"FAM3A plays crucial roles in controlling PDX1 and insulin expressions in pancreatic beta cells.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31944392","citation_count":17,"is_preprint":false},{"pmid":"36470472","id":"PMC_36470472","title":"FAM3A maintains metabolic homeostasis by interacting with F1-ATP synthase to regulate the activity and assembly of ATP synthase.","date":"2022","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/36470472","citation_count":17,"is_preprint":false},{"pmid":"35995281","id":"PMC_35995281","title":"Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis.","date":"2022","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/35995281","citation_count":16,"is_preprint":false},{"pmid":"29241198","id":"PMC_29241198","title":"FAM3A Protects Against Glutamate-Induced Toxicity by Preserving Calcium Homeostasis in Differentiated PC12 Cells.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29241198","citation_count":16,"is_preprint":false},{"pmid":"29802941","id":"PMC_29802941","title":"Exercise induced improvements in insulin sensitivity are concurrent with reduced NFE2/miR-432-5p and increased FAM3A.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29802941","citation_count":16,"is_preprint":false},{"pmid":"31208715","id":"PMC_31208715","title":"FAM3A protects chondrocytes against interleukin-1β-induced apoptosis through regulating PI3K/Akt/mTOR pathway.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31208715","citation_count":14,"is_preprint":false},{"pmid":"38937853","id":"PMC_38937853","title":"PANX1-mediated ATP release confers FAM3A's suppression effects on hepatic gluconeogenesis and lipogenesis.","date":"2024","source":"Military Medical Research","url":"https://pubmed.ncbi.nlm.nih.gov/38937853","citation_count":13,"is_preprint":false},{"pmid":"35144334","id":"PMC_35144334","title":"Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway.","date":"2022","source":"Endocrinology and metabolism (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/35144334","citation_count":13,"is_preprint":false},{"pmid":"38185473","id":"PMC_38185473","title":"Enhanced TROSY Effect in [2-19 F, 2-13 C] Adenosine and ATP Analogs Facilitates NMR Spectroscopy of Very Large Biological RNAs in Solution.","date":"2024","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/38185473","citation_count":11,"is_preprint":false},{"pmid":"27688071","id":"PMC_27688071","title":"Transcriptional regulation analysis of FAM3A gene and its effect on adipocyte differentiation.","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/27688071","citation_count":8,"is_preprint":false},{"pmid":"37056143","id":"PMC_37056143","title":"The circular RNA Rap1b promotes Hoxa5 transcription by recruiting Kat7 and leading to increased Fam3a expression, which inhibits neuronal apoptosis in acute ischemic stroke.","date":"2023","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/37056143","citation_count":8,"is_preprint":false},{"pmid":"39362520","id":"PMC_39362520","title":"Fam3a-mediated prohormone convertase switch in α-cells regulates pancreatic GLP-1 production in an Nr4a2-Foxa2-dependent manner.","date":"2024","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/39362520","citation_count":7,"is_preprint":false},{"pmid":"34853925","id":"PMC_34853925","title":"FAM3A Ameliorates Brain Impairment Induced by Hypoxia-Ischemia in Neonatal Rat.","date":"2021","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34853925","citation_count":7,"is_preprint":false},{"pmid":"40015605","id":"PMC_40015605","title":"KLF4 regulates FAM3A to promotes angiotensin II-induced proliferation and migration of vascular smooth muscle cells through the PI3K/AKT signaling pathway.","date":"2025","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/40015605","citation_count":7,"is_preprint":false},{"pmid":"39182087","id":"PMC_39182087","title":"Circulating extracellular vesicle-derived miR-1299 disrupts hepatic glucose homeostasis by targeting the STAT3/FAM3A axis in gestational diabetes mellitus.","date":"2024","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39182087","citation_count":6,"is_preprint":false},{"pmid":"34592773","id":"PMC_34592773","title":"Intracellular ATP Signaling Contributes to FAM3A-Induced PDX1 Upregulation in Pancreatic Beta Cells.","date":"2021","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/34592773","citation_count":5,"is_preprint":false},{"pmid":"37014466","id":"PMC_37014466","title":"FAM3A Deficiency - Induced Mitochondrial Dysfunction Underlies Post-Infarct Mortality and Heart Failure.","date":"2023","source":"Journal of cardiovascular translational research","url":"https://pubmed.ncbi.nlm.nih.gov/37014466","citation_count":3,"is_preprint":false},{"pmid":"37474885","id":"PMC_37474885","title":"FAM3A mediates the phenotypic switch of human aortic smooth muscle cells stimulated with oxidised low-density lipoprotein by influencing the PI3K-AKT pathway.","date":"2023","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/37474885","citation_count":2,"is_preprint":false},{"pmid":"41353211","id":"PMC_41353211","title":"FAM3A drives uncoupling of muscle lipid accumulation and insulin resistance depending on insulin receptor.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41353211","citation_count":1,"is_preprint":false},{"pmid":"40611502","id":"PMC_40611502","title":"FAM3A: a novel mitochondrial protein for the treatment of ischemic diseases.","date":"2025","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/40611502","citation_count":1,"is_preprint":false},{"pmid":"33799273","id":"PMC_33799273","title":"Establishment of a human iPSC line XMDYYYi001-A from a patient with Becker muscular dystrophy harboring duplications of exons 2-19 in dystrophin gene.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33799273","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.29.25332348","title":"Healthy diet metrics for children and adolescents and their suitability for global monitoring: a critical review","date":"2025-07-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.29.25332348","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.01.25330285","title":"Universal subconstructs of a healthy diet for children and adolescents: A critical review","date":"2025-07-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.01.25330285","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":22904,"output_tokens":6857,"usd":0.085783,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16120,"output_tokens":5121,"usd":0.104313,"stage2_stop_reason":"end_turn"},"total_usd":0.190096,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"FAM3A is localized in mitochondria, where it increases ATP production and secretion in hepatocytes. Released ATP activates P2 receptors, triggering PLC/IP3R-mediated Ca2+ elevation, which activates calmodulin (CaM), which in turn activates PI3K p110α/Akt signaling in an insulin-independent manner to suppress hepatic gluconeogenesis and lipogenesis.\",\n      \"method\": \"Subcellular fractionation, siRNA knockdown, adenoviral overexpression, pharmacological inhibition of P2 receptors/PLC/IP3R/CaM, in vivo mouse models (db/db, HFD)\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal pharmacological inhibitors, genetic KD/OE, in vivo and in vitro confirmation, replicated across multiple subsequent studies\",\n      \"pmids\": [\"24806753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PPARγ directly binds a peroxisome proliferator response element (PPRE) at -1258/-1246 in the human FAM3A promoter to transcriptionally activate FAM3A expression; site-directed mutagenesis of this PPRE abolished the stimulatory effect.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), site-directed mutagenesis, PPARγ agonist/antagonist treatment, PPARγ overexpression\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP plus mutagenesis plus reporter assay in single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23562554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FAM3A localizes to mitochondria in VSMCs and promotes ATP production and release. Released ATP activates the P2Y1 receptor to stimulate Akt (PI3K-dependent) and ERK1/2 (PI3K-independent) pathways, driving VSMC proliferation and migration. FAM3A overexpression exacerbates neointima formation after balloon injury in rat carotid artery.\",\n      \"method\": \"Subcellular fractionation, adenoviral overexpression, siRNA knockdown, P2 receptor antagonist suramin, P2Y1 siRNA knockdown, PI3K inhibitor, in vivo rat balloon injury model\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain/loss-of-function, pathway dissection with selective inhibitors, in vivo model; replicated in subsequent studies\",\n      \"pmids\": [\"24857820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NFE2 transcriptionally induces miR-423-5p, which directly targets FAM3A mRNA to repress its expression, thereby suppressing the FAM3A-ATP-Akt pathway, promoting hepatic gluconeogenesis and lipogenesis under obese conditions.\",\n      \"method\": \"miRNA target site prediction + luciferase reporter, hepatic adenoviral miR-423-5p overexpression/inhibition, NFE2 overexpression, in vivo mouse models (db/db, HFD)\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase validation of direct miRNA targeting, gain/loss-of-function in vivo and in vitro, pathway epistasis confirmed\",\n      \"pmids\": [\"28411267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Stat3 transcriptionally activates Fam3a in muscle stem cells; Fam3a is a secreted cytokine-like protein that promotes oxidative phosphorylation/mitochondrial respiration to drive myogenic commitment and skeletal muscle development. Recombinant Fam3a rescues mitochondrial respiration and myogenic commitment defects in Stat3-ablated muscle stem cells.\",\n      \"method\": \"Stat3 genetic ablation, recombinant Fam3a treatment in vitro and in vivo, Fam3a knockdown/KO in mice, Seahorse respirometry, myogenic differentiation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Stat3 upstream of Fam3a), rescue experiment with recombinant protein in vitro and in vivo, multiple orthogonal readouts\",\n      \"pmids\": [\"30996264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FAM3A localized to mitochondria promotes ATP production in 3T3-L1 preadipocytes; released ATP activates P2 receptors to stimulate Akt phosphorylation, which enhances adipogenesis. P2 receptor inhibition blocks FAM3A-induced adipogenesis.\",\n      \"method\": \"Subcellular fractionation, adenoviral overexpression, siRNA knockdown, P2 receptor antagonist, ATP measurement, lipid staining\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function plus pharmacological inhibition, single lab\",\n      \"pmids\": [\"28515350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FAM3A protects against liver ischemia-reperfusion injury by activating Akt survival pathway (ATP-P2 receptor-dependent), repressing apoptosis, inflammation, and oxidative stress; PPARγ agonist rosiglitazone's hepatoprotective effects are dependent on FAM3A.\",\n      \"method\": \"FAM3A-deficient (KO) mice, rosiglitazone treatment, hepatocyte overexpression/deficiency, P2 receptor inhibition, in vivo IRI model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO + pharmacological dependence demonstrated, single lab\",\n      \"pmids\": [\"28562339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Endothelial FAM3A (mitochondrial) increases ATP production and secretion; extracellular ATP activates P2 receptors to elevate cytosolic Ca2+, which enhances CREB phosphorylation and CREB recruitment to the VEGFA promoter, thereby activating VEGFA transcription and promoting angiogenesis.\",\n      \"method\": \"Adenoviral and AAV-mediated overexpression/knockdown, tube formation/migration/proliferation assays, hind limb ischemia mouse model, intracellular Ca2+ imaging, ChIP/promoter analysis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function in vitro and in vivo, mechanistic pathway traced to VEGFA promoter, single lab\",\n      \"pmids\": [\"31000420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In VSMCs, Angiotensin II activates HSF1 (heat shock factor 1), which transcriptionally upregulates FAM3A expression; elevated FAM3A enhances ATP production and activates the ATP-P2 receptor pathway, promoting VSMC phenotypic switch from contractile to proliferative. VSMC-specific FAM3A deletion reduces vessel contractility, blood pressure, and attenuates Ang II-induced hypertension and cardiac hypertrophy in mice.\",\n      \"method\": \"VSMC-specific Fam3a conditional KO mice, Ang II infusion model, HSF1 ChIP/overexpression, HSF1 inhibitor treatment, spontaneously hypertensive rats\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO with clear phenotype, upstream regulator (HSF1) identified by ChIP, pharmacological validation with HSF1 inhibitor, replicated in multiple hypertensive models\",\n      \"pmids\": [\"32279581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FAM3A plays crucial roles in pancreatic β cells: it promotes ATP synthesis, elevates cytosolic Ca2+ to stimulate insulin secretion, and releases ATP extracellularly to activate CaM as a co-activator of FOXA2, stimulating PDX1 gene transcription. β cell-specific FAM3A KO mice display markedly blunted insulin secretion and glucose intolerance.\",\n      \"method\": \"β cell-specific FAM3A KO mice, islet-specific adenoviral overexpression, CaM inhibitor, FOXA2 ChIP on PDX1 promoter, Ca2+ measurement, glucose tolerance test\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO, mechanistic pathway traced to PDX1 transcription via CaM-FOXA2, multiple orthogonal methods\",\n      \"pmids\": [\"31944392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Doxepin stimulates the nuclear translocation of HNF4α, which then promotes FAM3A transcription in hepatocytes; FAM3A deficiency abolishes doxepin's effects on ATP production, Akt activation, gluconeogenesis suppression, and lipid reduction.\",\n      \"method\": \"Drug-repurposing screen, HNF4α nuclear translocation assay, FAM3A KO mice on HFD, in vivo metabolic phenotyping\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FAM3A KO epistasis establishes pathway dependence, HNF4α nuclear translocation shown, single lab\",\n      \"pmids\": [\"32312868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FAM3A localizes to the mitochondrial matrix where it physically interacts with F1-ATP synthase (F1-ATPS) to directly activate ATP synthesis; released ATP subsequently activates P2 receptor-Akt-CREB signaling to induce FOXD3 expression. FOXD3 synchronously stimulates transcription of ATP synthase subunit genes and assembly factors to increase ATP synthase assembly and capacity, constituting a positive regulatory loop.\",\n      \"method\": \"Subcellular fractionation, co-immunoprecipitation (FAM3A with F1-ATPS), FOXD3 KO/KD, CREB pathway inhibition, RNA sequencing, in vivo FAM3A-deficient mice with metabolic phenotyping\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct physical interaction by co-IP, functional consequence demonstrated, epistatic loop confirmed by FOXD3 KO, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36470472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FAM3A-induced ATP release activates P2 receptors, promoting CaM translocation from cytoplasm to nucleus, where CaM acts as a co-activator of FOXA2 to transcribe CPT2 (carnitine palmitoyltransferase 2), increasing fatty acid oxidation and reducing lipid deposition. Imipramine activates this FAM3A-ATP-CaM-FOXA2-CPT2 pathway; FAM3A deficiency abolishes imipramine's lipid-lowering effect.\",\n      \"method\": \"RNA sequencing, CaM nuclear translocation assay, FOXA2 ChIP on CPT2 promoter, FAM3A KO mice on HFD, imipramine administration\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomic identification of downstream target, ChIP, CaM nuclear localization assay, KO epistasis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"35995281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FAM3A induces KLF4 ubiquitination and reduces its phosphorylation and nuclear localization in VSMCs, maintaining well-differentiated VSMC status and inhibiting VSMC transformation toward macrophage-, chondrocyte-, osteogenic-, mesenchymal-, and fibroblast-like phenotypes, thereby attenuating abdominal aortic aneurysm (AAA) formation.\",\n      \"method\": \"FAM3A overexpression/supplementation in murine AAA models, ubiquitination assays, KLF4 phosphorylation and nuclear localization assays, single-cell analyses, AAA histology\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KLF4 ubiquitination and nuclear localization demonstrated, in vivo rescue, single lab\",\n      \"pmids\": [\"37660071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FAM3A stimulates expression of the ATP-permeable channel PANX1 via HSF1 in hepatocytes; PANX1 mediates ATP release required for FAM3A's suppression of hepatic gluconeogenesis and lipogenesis. FAM3A overexpression fails to inhibit gluconeogenic/lipogenic genes in PANX1-deficient hepatocytes, establishing PANX1 as the conduit for FAM3A-driven ATP release.\",\n      \"method\": \"Co-immunoprecipitation with mass spectrometry, PANX1 global KO mice, hepatic PANX1 overexpression/knockdown via adenovirus/AAV, metabolic tolerance tests, OGTT/ITT/PTT, FAM3A overexpression in PANX1-KO hepatocytes\",\n      \"journal\": \"Military Medical Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP/MS for protein-protein interaction, genetic KO epistasis, in vivo and in vitro validation, multiple metabolic readouts\",\n      \"pmids\": [\"38937853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In pancreatic α-cells, FAM3A deficiency increases Nr4a2 expression; Nr4a2 forms a complex with FOXA2 to facilitate FOXA2 nuclear localization, and FOXA2 negatively regulates PCSK1 (PC1/3) transcription at specific promoter binding sites. Loss of α-cell FAM3A therefore de-represses PC1/3, shifting proglucagon processing from glucagon toward GLP-1 production, improving glucose tolerance via paracrine insulin secretion.\",\n      \"method\": \"α cell-specific Fam3a KO mice, transcriptomic analysis, Nr4a2 siRNA/overexpression, FOXA2 nuclear translocation assay, dual-luciferase reporter (Pcsk1 promoter), Nr4a2-FOXA2 co-IP, scRNA-seq correlation analysis, Ex9 GLP-1R antagonist in vivo\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO, luciferase reporter with promoter mutagenesis, co-IP for Nr4a2-FOXA2 complex, in vivo rescue with receptor antagonist, multiple orthogonal methods\",\n      \"pmids\": [\"39362520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FAM3A promotes PI3K/AKT/NRF2 signaling to block mitochondrial ROS accumulation; excess mt-ROS activates the NLRP3 inflammasome and Caspase-1, which cleaves GSDMD, pro-IL-1β, and pro-IL-18 to mediate pyroptosis in renal tubular cells. FAM3A KO worsens AKI and tubular pyroptosis, while FAM3A overexpression or NRF2 activator alleviates it; NRF2 deletion blocks FAM3A's anti-pyroptotic function.\",\n      \"method\": \"FAM3A KO and overexpression in renal ischemia/reperfusion model, NRF2 activator/inhibitor, Caspase-1/GSDMD cleavage assays, NLRP3 inflammasome activation assays, mt-ROS measurement\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO/OE with epistasis through NRF2, mechanistic pathway traced to pyroptosis effectors, single lab\",\n      \"pmids\": [\"38875957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FAM3A is subcellularly located in mitochondria of neuronal HT22 cells. FAM3A overexpression protects against H2O2-induced injury by reducing ROS and preserving ATP production; PI3K/Akt (but not MEK/ERK) pathway inhibition partially abolishes FAM3A-induced neuroprotection.\",\n      \"method\": \"Fluorescence subcellular localization, lentiviral overexpression, selective kinase inhibitors (PI3K/Akt vs MEK/ERK), cell viability, flow cytometry apoptosis, cytochrome c release, caspase-3 activation\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — localization confirmed, pathway inhibitor dissection, single lab, no rescue with reconstituted protein\",\n      \"pmids\": [\"26492522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FAM3A overexpression attenuates ER stress-induced mitochondrial dysfunction in neuronal HT22 cells by inverting tunicamycin-induced decrease of Wnt signaling through the CHOP pathway; CHOP siRNA knockdown confirmed FAM3A's protection is mediated via CHOP-Wnt axis.\",\n      \"method\": \"Lentiviral overexpression, tunicamycin ER stress model, CHOP siRNA, mitochondrial membrane potential, cytochrome c release, mitochondrial swelling/Ca2+ buffering in isolated mitochondria\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isolated mitochondria experiments plus CHOP siRNA epistasis, single lab\",\n      \"pmids\": [\"26939760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FAM3A overexpression in glutamate-injured PC12 neurons decreases surface expression of mGluR1/5, disrupts the STIM1-Orai1 interaction (confirmed by co-immunoprecipitation), and attenuates store-operated Ca2+ entry (SOCE) and IP3R-mediated ER Ca2+ release, thereby preserving intracellular Ca2+ homeostasis and reducing neuronal apoptosis.\",\n      \"method\": \"Co-immunoprecipitation (STIM1/Orai1), Ca2+ imaging, lentiviral overexpression, western blot for receptor surface expression, thapsigargin-induced SOCE assay\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP for STIM1-Orai1 disruption by FAM3A, Ca2+ imaging, single lab\",\n      \"pmids\": [\"29241198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"C/EBPβ directly binds to the FAM3A promoter and acts as a transcriptional activator; mutation of C/EBPβ binding sites dramatically reduces FAM3A promoter activity. FAM3A overexpression inhibits preadipocyte-to-adipocyte differentiation.\",\n      \"method\": \"Dual luciferase reporter, electrophoretic mobility shift assay (EMSA), C/EBPβ binding site mutagenesis, FAM3A overexpression with Oil Red O staining\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EMSA and reporter mutagenesis for transcriptional regulation, functional differentiation assay, single lab\",\n      \"pmids\": [\"27688071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Both intracellular and extracellular ATP contribute to FAM3A-induced PDX1 expression, insulin secretion, and β-cell proliferation. FAM3A-induced Ca2+ elevation, PDX1 expression, and insulin secretion are repressed by P2 receptor inhibitors, L-type Ca2+ channel inhibitors, or CaM inhibitor in pancreatic β cells.\",\n      \"method\": \"siRNA transfection in mouse islets, in vivo glucose tolerance test, P2 receptor inhibitor, L-type Ca2+ channel inhibitor, CaM inhibitor, intracellular/extracellular ATP measurement\",\n      \"journal\": \"Experimental and clinical endocrinology & diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors dissect pathway, in vivo siRNA epistatsis, single lab, consistent with prior study (PMID 31944392)\",\n      \"pmids\": [\"34592773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FAM3A deficiency in cardiomyocytes reduces basal, ATP-linked respiration and respiratory reserve, and is associated with enlarged mitochondria, elevated mitochondrial Ca2+, higher mPTP opening, lower mitochondrial membrane potential, and elevated apoptosis. The mitochondrial dynamics protein Opa1 contributes to FAM3A's effects in cardiomyocytes.\",\n      \"method\": \"Fam3a-/- mice with MI model, Seahorse respirometry in isolated cardiomyocytes, transmission electron microscopy, mPTP opening assay, mitochondrial Ca2+ and membrane potential measurements, Opa1 analysis\",\n      \"journal\": \"Journal of cardiovascular translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO phenotype with multiple mitochondrial function readouts, Opa1 identified as contributing factor, single lab\",\n      \"pmids\": [\"37014466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF4 directly binds to the FAM3A promoter (confirmed by CHIP and luciferase assays) and transcriptionally upregulates FAM3A expression in Ang II-stimulated VSMCs, with FAM3A mediating Ang II-induced proliferation and migration through PI3K/AKT pathway activation.\",\n      \"method\": \"Bioinformatics, luciferase reporter, chromatin immunoprecipitation (CHIP), KLF4 KD/OE, FAM3A siRNA, PI3K/AKT western blot, EdU proliferation, transwell/scratch migration\",\n      \"journal\": \"Peptides\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and luciferase, functional epistasis, single lab\",\n      \"pmids\": [\"40015605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Hoxa13 binds to the FAM3A promoter and enhances its transcriptional activity in neuronal cells; the Snhg8/miR-384/Hoxa13/FAM3A axis regulates chronic cerebral ischemia-induced neuronal apoptosis.\",\n      \"method\": \"Promoter activity assay (Hoxa13 binding to FAM3A promoter), miRNA target site validation, Snhg8 and miR-384 overexpression/knockdown, in vivo ischemia mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding assay for Hoxa13, functional apoptosis epistasis shown, single lab\",\n      \"pmids\": [\"31165722\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FAM3A is a mitochondrial matrix protein that physically interacts with F1-ATP synthase to directly stimulate ATP synthesis; the resulting intracellular ATP is released extracellularly via the PANX1 channel (regulated by HSF1) and via other mechanisms, and extracellular ATP activates P2 purinergic receptors to trigger downstream signaling cascades—including Ca2+/calmodulin-dependent PI3K-p110α/Akt activation, CREB-FOXD3-mediated ATP synthase assembly reinforcement, CaM-FOXA2-driven CPT2 and PDX1 transcription, and VEGFA-mediated angiogenesis—that collectively suppress hepatic gluconeogenesis and lipogenesis, promote β-cell insulin secretion and PDX1 expression, drive muscle stem cell myogenic commitment via oxidative phosphorylation, regulate VSMC phenotype and blood pressure, and protect multiple cell types from oxidative, ischemic, and ER stress-induced injury; FAM3A expression is transcriptionally regulated by PPARγ, HNF4α, C/EBPβ, STAT3, HSF1, KLF4, and Hoxa13, and is repressed post-transcriptionally by miR-423-5p (driven by NFE2) and miR-1299.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FAM3A is a mitochondrial matrix protein that drives ATP-dependent signaling to govern cellular metabolism, survival, and proliferation across hepatic, pancreatic, vascular, muscle, and neuronal tissues [#0, #11]. Within the mitochondrial matrix it physically interacts with F1-ATP synthase to directly stimulate ATP synthesis, and the resulting ATP is released extracellularly—in hepatocytes through the HSF1-regulated, ATP-permeable channel PANX1—to act in an autocrine/paracrine manner [#11, #14]. Released ATP engages P2 purinergic receptors (including P2Y1), triggering PLC/IP3R-mediated Ca2+ elevation and calmodulin activation that drives PI3K-p110\\u03b1/Akt signaling independently of insulin [#0, #2]. Downstream of this ATP-P2-Akt axis, FAM3A feeds multiple transcriptional programs: a CREB-FOXD3 loop that reinforces ATP synthase assembly [#11], a calmodulin-FOXA2 axis driving CPT2-dependent fatty acid oxidation and PDX1 transcription [#12, #9], and CREB-driven VEGFA expression for angiogenesis [#7]. Functionally, FAM3A suppresses hepatic gluconeogenesis and lipogenesis [#0, #14], promotes \\u03b2-cell insulin secretion and survival [#9], regulates pancreatic \\u03b1-cell proglucagon processing via an Nr4a2-FOXA2-PCSK1 axis [#15], drives muscle stem cell myogenic commitment through oxidative phosphorylation [#4], controls VSMC phenotype and blood pressure [#8, #13], and protects diverse cell types from oxidative, ischemic, and ER stress by preserving ATP, limiting ROS, and engaging Akt/NRF2 survival signaling [#6, #16, #17]. FAM3A transcription is activated by PPAR\\u03b3, HNF4\\u03b1, C/EBP\\u03b2, STAT3, HSF1, KLF4, and Hoxa13, and is repressed post-transcriptionally by miR-423-5p [#1, #20, #4, #8, #23, #3].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Established a transcriptional activator and a regulatory non-coding RNA circuit controlling FAM3A in neurons, linking it to ischemic neuronal apoptosis before its biochemical role was clear.\",\n      \"evidence\": \"Hoxa13 promoter-binding assay and Snhg8/miR-384 gain/loss-of-function in an in vivo cerebral ischemia mouse model\",\n      \"pmids\": [\"31165722\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define FAM3A's molecular activity downstream of transcription\", \"Promoter binding not extended to direct biochemical FAM3A function\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified the first direct transcriptional activator of FAM3A, placing it downstream of nuclear receptor signaling.\",\n      \"evidence\": \"Luciferase reporter, ChIP, and PPRE site-directed mutagenesis with PPAR\\u03b3 agonist/antagonist in human cells\",\n      \"pmids\": [\"23562554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish FAM3A's downstream effector mechanism\", \"Physiological context of PPAR\\u03b3-FAM3A axis not tested in vivo here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined FAM3A's core mechanism—mitochondrial ATP production and release activating an extracellular P2 receptor-Ca2+-CaM-PI3K/Akt cascade to suppress hepatic gluconeogenesis and lipogenesis insulin-independently.\",\n      \"evidence\": \"Subcellular fractionation, KD/OE, orthogonal pharmacological inhibition of P2/PLC/IP3R/CaM, and db/db and HFD mouse models\",\n      \"pmids\": [\"24806753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify how FAM3A mechanistically stimulates ATP synthesis\", \"ATP release conduit not yet identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed the same mitochondrial ATP-P2 receptor mechanism operates in vascular smooth muscle, where it drives proliferation/migration via P2Y1-Akt and ERK1/2, generalizing FAM3A beyond liver.\",\n      \"evidence\": \"Fractionation, reciprocal OE/KD, suramin/P2Y1 siRNA/PI3K inhibitors, and rat carotid balloon injury model\",\n      \"pmids\": [\"24857820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Branch point between Akt and ERK1/2 downstream of P2Y1 not resolved\", \"No direct ATP synthase interaction shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended FAM3A's cytoprotective function to neurons, linking ATP preservation and ROS reduction to PI3K/Akt-dependent survival under oxidative stress.\",\n      \"evidence\": \"Subcellular localization, lentiviral OE, selective PI3K/Akt vs MEK/ERK inhibitors, apoptosis and cytochrome c assays in HT22 cells\",\n      \"pmids\": [\"26492522\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No rescue with reconstituted protein\", \"Mechanism of ROS reduction not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Added C/EBP\\u03b2 as a direct FAM3A activator and uncovered ER-stress protection via a CHOP-Wnt axis, broadening transcriptional control and stress-protective scope.\",\n      \"evidence\": \"Luciferase/EMSA/mutagenesis (C/EBP\\u03b2); tunicamycin model with CHOP siRNA and isolated-mitochondria assays in HT22 cells\",\n      \"pmids\": [\"27688071\", \"26939760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How FAM3A modulates Wnt/CHOP signaling biochemically is unresolved\", \"C/EBP\\u03b2 regulation not tested in vivo\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified miR-423-5p (driven by NFE2) as a direct post-transcriptional repressor of FAM3A, providing a mechanism for FAM3A downregulation in obesity, and extended the ATP-Akt axis to adipogenesis and liver ischemia protection.\",\n      \"evidence\": \"Luciferase miRNA targeting + in vivo miR-423-5p/NFE2 manipulation; P2-inhibitor adipogenesis assays; FAM3A KO + rosiglitazone IRI model\",\n      \"pmids\": [\"28411267\", \"28515350\", \"28562339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specificity of miR-423-5p regulation incompletely mapped\", \"Opposite metabolic outcomes (adipogenesis vs gluconeogenesis suppression) not reconciled mechanistically\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a neuronal Ca2+-homeostasis mechanism in which FAM3A disrupts STIM1-Orai1 and dampens store-operated Ca2+ entry to reduce apoptosis.\",\n      \"evidence\": \"STIM1/Orai1 co-IP, Ca2+ imaging, SOCE assays, and surface receptor blots in glutamate-injured PC12 cells\",\n      \"pmids\": [\"29241198\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single co-IP without reciprocal/structural validation\", \"Relationship between this Ca2+ effect and the mitochondrial ATP role unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established FAM3A as a STAT3-induced secreted factor promoting oxidative phosphorylation and myogenic commitment, and traced an endothelial CREB-VEGFA angiogenic program.\",\n      \"evidence\": \"Stat3 ablation + recombinant Fam3a rescue, Seahorse, Fam3a KO mice; endothelial OE/KD with hind-limb ischemia model and VEGFA promoter ChIP\",\n      \"pmids\": [\"30996264\", \"31000420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation of mitochondrial vs secreted-cytokine modes of action not addressed\", \"Receptor mediating any secreted FAM3A action unidentified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapped tissue-specific transcriptional inputs and effector programs: HSF1-driven FAM3A in VSMC hypertension, HNF4\\u03b1-driven hepatic FAM3A, and a \\u03b2-cell CaM-FOXA2-PDX1 axis controlling insulin secretion.\",\n      \"evidence\": \"VSMC- and \\u03b2-cell-specific Fam3a KO mice, HSF1 ChIP/inhibitor, doxepin/HNF4\\u03b1 translocation, FOXA2 ChIP on PDX1 promoter, Ang II and GTT models\",\n      \"pmids\": [\"32279581\", \"31944392\", \"32312868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single mitochondrial protein produces tissue-divergent transcriptional outputs not unified\", \"Direct ATP synthase engagement still inferred, not shown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved FAM3A's biochemical mechanism by demonstrating direct physical interaction with F1-ATP synthase to stimulate ATP synthesis, and uncovered a CREB-FOXD3 feed-forward loop reinforcing ATP synthase assembly, plus a CaM-FOXA2-CPT2 fatty-acid-oxidation arm.\",\n      \"evidence\": \"Co-IP (FAM3A-F1-ATPS), FOXD3 KO/KD, CREB inhibition, RNA-seq; FOXA2 ChIP on CPT2 promoter with FAM3A KO + imipramine HFD models\",\n      \"pmids\": [\"36470472\", \"35995281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of FAM3A-F1-ATPS interaction unknown\", \"Stoichiometry and direct catalytic effect on ATP synthase not quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined non-ATP regulatory outputs in vasculature—FAM3A induces KLF4 ubiquitination to maintain VSMC differentiation and attenuate aneurysm—and a KLF4 feedback loop activating FAM3A, alongside cardiomyocyte mitochondrial dynamics via Opa1.\",\n      \"evidence\": \"AAA models with KLF4 ubiquitination/nuclear-localization assays; KLF4 ChIP/luciferase; Fam3a-/- MI model with Seahorse, TEM, mPTP and Opa1 analysis\",\n      \"pmids\": [\"37660071\", \"40015605\", \"37014466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether KLF4 ubiquitination is ATP-dependent or a distinct activity unclear\", \"Mechanism linking FAM3A to Opa1 not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified PANX1 as the HSF1-induced conduit for FAM3A-driven ATP release in hepatocytes, defined a NRF2-dependent anti-pyroptotic mechanism, and uncovered an \\u03b1-cell Nr4a2-FOXA2-PCSK1 axis shifting proglucagon processing toward GLP-1.\",\n      \"evidence\": \"Co-IP/MS, PANX1 KO and hepatic OE/KD with metabolic tests; FAM3A KO/OE renal I/R with NRF2 epistasis and GSDMD/Caspase-1 assays; \\u03b1-cell-specific Fam3a KO with Pcsk1 luciferase and Nr4a2-FOXA2 co-IP\",\n      \"pmids\": [\"38937853\", \"38875957\", \"39362520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PANX1 is the universal ATP conduit across all FAM3A-expressing tissues untested\", \"How FAM3A loss elevates Nr4a2 mechanistically unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis and stoichiometry of FAM3A's interaction with F1-ATP synthase, and how a single mitochondrial protein generates tissue-divergent transcriptional and non-ATP (KLF4 ubiquitination, STIM1-Orai1) outputs, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of FAM3A or its ATP synthase complex\", \"Mechanism by which a matrix protein controls cytoplasmic/nuclear events beyond ATP release is unclear\", \"Whether secreted and mitochondrial FAM3A pools are functionally distinct is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [11, 0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 2, 5, 11, 17]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 12, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 7]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [16, 17, 18]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [11, 9, 12, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ATP5F1 (F1-ATP synthase)\", \"PANX1\", \"FOXD3\", \"FOXA2\", \"Nr4a2\", \"KLF4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":6,"faith_total":6,"faith_pct":100.0}}